Joe Biden Reveals He Won't Pardon Son Hunter If He's Convicted In Felony Gun Trial
Source: MEGA
Joe Biden revealed his position on potentially pardoning his only living son Hunter.
Jun. 6 2024, Published 5:15 p.M. ET
President Joe Biden revealed he would not pardon son Hunter Biden, who is currently on trial for felony gun charges, RadarOnline.Com has learned.
Biden shared why he would not pardon his son if convicted during an interview with ABC News' David Muir at the Normandy American Cemetery in France on the 80th anniversary of D-Day.
Article continues below advertisem*nt
Source: MEGA
Biden said he's ruled out the possibility of pardoning Hunter if he's convicted of felony gun charges.
During the interview, which covered a wide range of topics, Muir asked the 81-year-old president if he would accept the outcome of Hunter's trial, to which Biden answered, "Yes."
The news anchor then pressed if Biden had ruled out the possibility of pardoning his only living son if convicted, to which Biden also replied, "Yes."
Article continues below advertisem*nt
Source: MEGA
Hunter is currently on trial for charges related to his efforts to purchase a handgun in 2018 while allegedly addicted to drugs.
Article continues below advertisem*nt
Hunter is currently on trial in Wilmington, Delaware, for felony gun charges related to his attempt to purchase a handgun in 2018 while battling substance abuse addiction. Hunter pleaded not guilty to his charges in October 2023 after being indicted by special counsel David Weiss.
The case has made headlines as it's the first time the child of a sitting president has faced a criminal trial.
Article continues below advertisem*nt
Source: MEGA
Biden accused Donald Trump of 'trying to undermine' the justice system after being convicted of 34 felonies.
MORE ON:
Joe Biden
Article continues below advertisem*nt
While discussing the ongoing trial and justice system, Biden noted Donald Trump's historic hush-money trial, in which he was convicted of 34 felony charges of falsifying business records before the 2016 election to cover up his affair with adult film star Stormy Daniels.
The ex-president and presumptive Republican nominee denounced the trial as "rigged" and falsely claimed Biden brought it to keep him off the campaign trail.
Article continues below advertisem*nt
During his sit down with Muir, Biden hit back at Trump and claimed he was "trying to undermine" the justice system.
"He got a fair trial. The jury spoke," the president told Muir.
Never miss a story — sign up for the RadarOnline.Com newsletter to get your daily dose of dope. Daily. Breaking. Celebrity news. All free.
Article continues below advertisem*nt
Source: MEGA
Trump claimed his New York trial was 'rigged' and brought by Biden to keep him off the campaign trail.
Article continues below advertisem*nt
Since his conviction, Trump has seemingly tried to rewrite history as he awaits sentencing, in which he faces potential incarceration.
While Trump enthusiastically led "lock her up" chants aimed at his 2016 opponent Hillary Clinton, he now claimed he "thought it was terrible" when his MAGA supporters said it.
Article continues below advertisem*nt
"After we won against Hillary, people would say: Lock her up, lock her up," Trump told Sean Hannity in a recent interview. "And I said, wouldn't it be terrible if I locked up the wife of the president of the United States, former, and locked up the former secretary of state?"
"It's a terrible thing," the ex-president added.
New Lung Cancer Pill Produces "unprecedented" Results In Human Trial
The protein anaplastic lymphoma kinase (ALK) helps control cell growth. It's made by the ALK gene, which can be rearranged by some cancers, including non-small cell lung cancer (NSCLC), causing the cancer to grow and spread. One of the two main types of lung cancer – the other is small cell lung cancer – NSCLC accounts for around 80% to 85% of lung cancers, with ALK-positive tumors occurring in about 3% to 5% of those cases. ALK-positive NSCLC is typically more aggressive and seen in younger people with a light or non-smoking history.
Lorlatinib is a third-generation ALK inhibitor, the newest in a class of drugs that are the standard first-line treatment for patients with ALK-positive NSCLC. A recent international clinical trial led by the Peter MacCallum Cancer Center (Peter Mac) in Melbourne, Australia, assessed the drug's effect on long-term disease progression in patients with advanced ALK-positive NSCLC. The results were remarkable.
"To our knowledge, these results are unprecedented," said Peter Mac's Professor Ben Solomon, the study's lead and corresponding author, in an interview with The Guardian.
In the Phase III trial, 296 patients with previously untreated, advanced ALK-positive NSCLC were randomly assigned to receive either lorlatinib or crizotinib, a first-generation ALK inhibitor sold as Xalkori. Lorlatinib is given as a once-a-day tablet, while crizotinib is given twice daily. The study's primary endpoint was progression-free survival; the key secondary endpoint was overall survival. Another secondary endpoint was whether the cancer had metastasized to the brain.
Five years after treatment, 60% of patients given lorlatinib were still alive without signs of disease progression, compared to 8% of patients on crizotinib. There was also an 81% reduction in the risk of cancer progression or death and a 94% reduction in the progression of brain metastasis compared to crizotinib.
The current trial was an update on follow-up at the three-year mark, which showed similar progression-free survival and brain progression rates.
"This updated analysis shows that lorlatinib helped patients live longer without disease progression, with the majority of patients experiencing sustained benefit for over five years, including nearly all patients having protection from progression of disease in the brain," Solomon said
Consistent with the data from previous trials, Lorlatinib was associated with a higher incidence of adverse events than crizotinib, 77% versus 57%, mostly due to increased blood lipids (cholesterol and triglycerides). However, cardiovascular adverse events were similar between the treatment groups. Adverse events related to lorlatinib were manageable with a dose reduction without affecting the drug's efficacy. The progression-free survival rates and time-to-brain progression were similar in patients whose dose was reduced within the first 16 weeks and those who didn't take a reduced dose.
After five years of follow-up, the study's findings represent the longest progression-free survival data ever reported with any single-agent targeted treatment in advanced NSCLC and across all metastatic solid cancer tumors.
"These improvements in outcomes for patients with ALK-positive NSCLC represent a remarkable advancement in lung cancer," said Solomon.
The trial results were presented at the 2024 American Society of Clinical Oncology (ASCO) annual scientific meeting, currently being held in Chicago, and published simultaneously in the Journal of Clinical Oncology.
Source: Peter MacCallum Cancer Centre
Strong Buy Rating For Annexon Biosciences Amidst Promising ANX005 Clinical Trial Results And Market Potential
Analyst Derek Archila of Wells Fargo reiterated a Buy rating on Annexon Biosciences (ANNX – Research Report), retaining the price target of $10.00.
Derek Archila has given his Buy rating due to a combination of factors that indicate a strong potential for Annexon Biosciences. The clinical data for ANX005 at the 30mg/kg dose met significant statistical benchmarks in the Phase 3 GBS trial, demonstrating considerable efficacy with a 2.4-fold improvement on the primary endpoint. Additionally, the 30mg/kg dose showed statistically significant benefits on secondary endpoints, such as a reduction in the median number of days on artificial ventilation and time to walk independently, which are critical differentiators compared to existing treatments.The safety profile of ANX005 also contributed to the positive outlook, with reported adverse events being mild to moderate and the treatment being well-tolerated overall. The lack of serious safety concerns and the absence of dose-related adverse events with the 30mg/kg dose support the drug's approvability. Despite questions surrounding the higher 75mg/kg dose, the data for the lower dose alone provides a strong case for regulatory approval and market differentiation, particularly since there are currently no approved drugs for Guillain-Barre Syndrome (GBS). Archila's expectations for the stock to perform well are underpinned by these promising clinical outcomes and the unmet medical need in the GBS market.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $30.00 price target.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Annexon Biosciences (ANNX) Company Description:
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005; ANX007; and ANX009.
